Related Experiment Video
Updated: Aug 24, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Dextroamphetamine use during B-2 combat missions
David N Kenagy1, Christopher T Bird, Christopher M Webber
1Wilford Hall Medical Center, Lackland AFB, TX 78236-5300, USA. kenagyrd@earthlink.net
Introduction:
Fatigue among warriors can jeopardize mission success. Prescribed stimulant medications, in-flight sleep, and self-medication with caffeine can mitigate fatigue. During Operation Iraqi Freedom, pilots flew the B-2 bomber to targets in Iraq from one of two airfields. Sortie durations were long (16.9 h) from one field and very long (35.3 h) from the other. Controversy exists concerning the use of stimulant medication, in part because of a paucity of combat data.
Methods:
A retrospective analysis of 75 pilots who performed 94 combat sorties was performed. We examined the prevalence of the pilot's decision to use dextroamphetamine, caffeine, and in-flight sleep during combat. We compared demographic factors, the impact of one anti-fatigue tool on the use of others, stimulant benefit, and adverse effects.
Results:
Pilots on shorter missions used dextroamphetamine for 97% and in-flight naps for 13% of sorties. Those on longer missions used dextroamphetamine on 58% and naps on 94% of sorties. Stimulant use was not affected by pilot age, bomber experience, or long-duration experience. The opportunity to obtain in-flight sleep was limited by certain mission profiles, which influenced the decision to use dextroamphetamine. Among pilots who used the medication, 97% noted a benefit. Side effects and failure to observe benefits were uncommon.
Conclusions:
B-2 pilots in long-duration combat flight selectively employ dextroamphetamine, naps, and other fatigue countermeasures. Major determinants of these decisions are mission requirements and the pilot's experience with each measure and its effect.
More Related Videos
08:20Simultaneous Application of Transcranial Direct Current Stimulation during Virtual Reality Exposure
Published on: January 18, 2021
10:02Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
Published on: March 12, 2020
Related Concept Videos
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
CNS Stimulants: Psychedelic Agents